Clinical Trial Update: Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating docetaxel and carboplatin in metastatic castration-resistant prostate cancer with BRCA1/2 pathway inactivation; study completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: University of Washington | Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-11-17